Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...